neurim.com
INSOMNIA | Neurim Pharmaceuticals
http://www.neurim.com/products/circadin/insomnia
Insomnia is a subjective complaint encompassing delay in onset, insufficient duration or poor quality of sleep (non-restorative sleep). Not all three symptoms need to be present for the diagnosis of insomnia to be made. Importantly, sufferers feel tired or distressed during the day. Circadin receives marketing authorization in Honduras. Circadin is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders.
neurim.com
CIRCADIN® | Neurim Pharmaceuticals
http://www.neurim.com/products/circadin
Is approved for marketing as a patent-protected 2mg prolonged-release melatonin formulation. It mimics the physiological secretion profile of melatonin. Neurim’s database has shown that elderly patients suffering from primary insomnia secrete significantly lower levels of melatonin than those with good sleep quality. The rationale for the use of Circadin. The clinical development of Circadin. Garfinkel et al 1995. And by Leger et al 2004. Lemoine et al 2007. Luthringer et al 2009. Wade et al 2010. The ef...
neurim.com
DISCLAIMER | Neurim Pharmaceuticals
http://www.neurim.com/disclaimer
Information on this Website (www.neurim.com) other than historical information are forward-looking statements subject to risks and uncertainties. Actual results may differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection. Rechtlicher Hinweis für Besucher aus Deutschland. Circadin receives marketing authorization in Honduras.
neurim.com
CAREER | Neurim Pharmaceuticals
http://www.neurim.com/career
There are currently no open positions. Circadin receives marketing authorization in Honduras. Circadin is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders. Circadin 2mg (prolonged-release melatonin) is now commercially available in Peru.
neurim.com
NEWS | Neurim Pharmaceuticals
http://www.neurim.com/news
Aug 2, 2016. Circadin receives marketing authorization in Honduras. Jun 21, 2016. Circadin is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders ( Read more. Mar 3, 2016. Circadin 2mg (prolonged-release melatonin) is now commercially available in Peru. Mar 2, 2016. Circadin 2mg (prolonged-release melatonin) is now commercially available in Argentina. Jan 11, 2016. Oct 1, 2015. Sep 18, 2015. Mar 2, 2015. Sep 7, 2014. Sep 1, 2014. Neurim P...
neurim.com
ABOUT | Neurim Pharmaceuticals
http://www.neurim.com/about
Neurim Pharmaceuticals Ltd. is a drug discovery and development company, focused on the central nervous system (CNS), primarily in age-related disorders. Our main goal is to improve the quality of life. The company’s novel product for insomnia, was approved by the European Commission on the 29th June 2007 and is currently marketed in Europe, Asia-Pacific, Latin America, Africa and the Middle East. Other products are NCEs at preclinical and clinical development. Dr Moshe Laudon, who joined in 1992 and has...
neurim.com
CHRONIC INSOMNIA | Neurim Pharmaceuticals
http://www.neurim.com/products/circadin/chronic-insomnia
Circadin receives marketing authorization in Honduras. Circadin is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders. Circadin 2mg (prolonged-release melatonin) is now commercially available in Peru.
neurim.com
ASK A QUESTION | Neurim Pharmaceuticals
http://www.neurim.com/products/circadin/ask-a-question
Looking for more information about Circadin. Send us your questions and we will contact you shortly. Alternatively, you can contact us by email at ask@neurim.com. Circadin receives marketing authorization in Honduras. Circadin is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders. Circadin 2mg (prolonged-release melatonin) is now commercially available in Peru.
neurim.com
PIROMELATINE | Neurim Pharmaceuticals
http://www.neurim.com/products/piromelatine
Neurim Pharmaceuticals has developed and globally patented Piromelatine, a New Chemical Entity. Piromelatine is a melatonin MT1/2/3 and serotonin 5-HT-1A/1D receptors agonist developed for Sleep disorders and Alzheimer’s Disease. Piromelatine in insomnia patients. All potential effects of Piromelatine were demonstrated in relevant rodent models of central sensitivity syndrome and sleep maintenance ( Liu et al 2014. Pain ( Chen et al 2014. Neuroprotection and cardioprotection ( He et al 2013. Yu et al 2014.
neurim.com
PRODUCTS | Neurim Pharmaceuticals
http://www.neurim.com/products
2mg prolonged-release melatonin formulation, approved for use (up to 13 weeks) in treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years or over. Products in Clinical Phase. The Pediatric Prolonged-Release Melatonin has been designed to gradually release melatonin, mimicking the physiological secretion profile of melatonin that produces sustained plasma levels of melatonin for up to 8-10 hours. In order to establish the efficacy and safety of Pediatric Prolonge...
